(RTTNews) - LifeArc said that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, agreed to be acquired by ArcutisBiotherapeutics Inc. (ARQT). The Agreement values Ducentis at up to $400 million, including upfront cash payment of $16 million and Arcutis stock valued at about $14 million, plus future contingent payments based on development and commercial success.
Ducentis' lead pre-clinical asset, DS-234, is being developed for the treatment of atopic dermatitis, a rapidly growing, significantly underserved market.
Closing of the transaction will be subject to customary closing conditions.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
